Literature DB >> 22994849

Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays.

Nadia El-Farhan1, Alan Pickett, David Ducroq, Catherine Bailey, Kelly Mitchem, Nicola Morgan, Annie Armston, Laila Jones, Carol Evans, D Aled Rees.   

Abstract

OBJECTIVE: The serum cortisol response to the adrenocorticotrophin (ACTH) test is known to vary significantly by assay, but lower reference limits (LRL) for this response have not been established by the reference gas chromatography-mass spectrometry (GC-MS) method or modern immunoassays. We aimed to compare the normal cortisol response to ACTH stimulation using GC-MS with five widely used immunoassays. DESIGN, PATIENTS AND MEASUREMENTS: An ACTH test (250 μg iv ACTH1-24 ) was undertaken in 165 healthy volunteers (age, 20-66 years; 105 women, 24 of whom were taking an oestrogen-containing oral contraceptive pill [OCP]). Serum cortisol was measured using GC-MS, Advia Centaur (Siemens), Architect (Abbott), Modular Analytics E170 (Roche), Immulite 2000 (Siemens) and Access (Beckman) automated immunoassays. The estimated LRL for the 30 min cortisol response to ACTH was derived from the 2·5th percentile of log-transformed concentrations.
RESULTS: The GC-MS-measured cortisol response was normally distributed in males but not females, with no significant gender difference in baseline or post-ACTH cortisol concentration. Immunoassays were positively biased relative to GC-MS, except in samples from women on the OCP, who showed a consistent negative bias. The LRL for cortisol was method-specific [GC-MS: 420 nm; Architect: 430 nm; Centaur: 446 nm; Access 459 nm; Immulite (2000) 474 nm] and, for the E170, also gender-specific (female: 524 nm; male 574 nm). A separate LRL is necessary for women on the OCP.
CONCLUSIONS: Normal cortisol responses to the ACTH test are influenced significantly by assay and oestrogen treatment. We recommend the use of separate reference limits in premenopausal women on the OCP and warn users that cortisol measurements in this subgroup are subject to assay interference.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22994849     DOI: 10.1111/cen.12039

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  29 in total

1.  Assessment of the HPA Axis: Another New Test?

Authors:  Ashley Grossman
Journal:  Endocrine       Date:  2015-09-11       Impact factor: 3.633

2.  Case series of short synacthen tests supports using 9 am cortisol level to exclude adrenal insufficiency.

Authors:  Bernard Freudenthal; Daniel Beder; Arla Ogilvie
Journal:  Clin Med (Lond)       Date:  2016-06       Impact factor: 2.659

3.  Characterization of the serum and salivary cortisol response to the intravenous 250 µg ACTH1-24 stimulation test.

Authors:  Brendan J Nolan; Jane Sorbello; Nigel Brown; Goce Dimeski; Warrick J Inder
Journal:  Endocrine       Date:  2018-01-03       Impact factor: 3.633

4.  Plasma Free Cortisol in States of Normal and Altered Binding Globulins: Implications for Adrenal Insufficiency Diagnosis.

Authors:  Laura E Dichtel; Melanie Schorr; Claudia Loures de Assis; Elizabeth M Rao; Jessica K Sims; Kathleen E Corey; Puja Kohli; Patrick M Sluss; Michael J McPhaul; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

5.  Assessment of early morning serum cortisol levels in adult male patients with alcohol-related disorders.

Authors:  Barun K Chakrabarty; Karan Sud; Prosenjit Ganguli; S A Khan
Journal:  Med J Armed Forces India       Date:  2020-11-26

6.  Dietary sodium intake and cortisol measurements.

Authors:  Angela X Chen; Andrea V Haas; Gordon H Williams; Anand Vaidya
Journal:  Clin Endocrinol (Oxf)       Date:  2020-06-24       Impact factor: 3.478

7.  Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection.

Authors:  Sophie A Clarke; Maria Phylactou; Bijal Patel; Edouard G Mills; Beatrice Muzi; Chioma Izzi-Engbeaya; Sirazum Choudhury; Bernard Khoo; Karim Meeran; Alexander N Comninos; Ali Abbara; Tricia Tan; Waljit S Dhillo
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

8.  The clinical course after glucocorticoid treatment in patients with inflammatory bowel disease is linked to suppression of the hypothalamic-pituitary-adrenal axis: a retrospective observational study.

Authors:  Aghil Ibrahim; Per Dahlqvist; Tommy Olsson; David Lundgren; Mårten Werner; Ole B Suhr; Pontus Karling
Journal:  Therap Adv Gastroenterol       Date:  2017-09-21       Impact factor: 4.409

Review 9.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy
Journal:  J Clin Endocrinol Metab       Date:  2016-01-13       Impact factor: 5.958

10.  Differentiating 11β-hydroxylase deficiency from primary glucocorticoid resistance syndrome in male precocity: real challenge in low-income countries.

Authors:  Sananda Majumder; Partha Pratim Chakraborty; Prakash Chandra Ghosh; Mitali Bera
Journal:  BMJ Case Rep       Date:  2020-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.